Synthesis and Characterization of New Ruthenium (II) Complexes of Stoichiometry [Ru(<i>p</i>-Cymene)Cl<sub>2</sub>L] and Their Cytotoxicity against HeLa-Type Cancer Cells
Marta G. Fuster,
Imane Moulefera,
Mercedes G. Montalbán,
José Pérez,
Gloria Víllora,
Gabriel García
Affiliations
Marta G. Fuster
Departamento de Ingeniería Química, Facultad de Química, Campus Regional de Excelencia “Campus Mare Nostrum”, Universidad de Murcia, 30071 Murcia, Spain
Imane Moulefera
Departamento de Ingeniería Química, Facultad de Química, Campus Regional de Excelencia “Campus Mare Nostrum”, Universidad de Murcia, 30071 Murcia, Spain
Mercedes G. Montalbán
Departamento de Ingeniería Química, Facultad de Química, Campus Regional de Excelencia “Campus Mare Nostrum”, Universidad de Murcia, 30071 Murcia, Spain
José Pérez
Departamento de Ingeniería Química y Medioambiental, ETSII, Universidad Politécnica de Cartagena, 30203 Cartagena, Spain
Gloria Víllora
Departamento de Ingeniería Química, Facultad de Química, Campus Regional de Excelencia “Campus Mare Nostrum”, Universidad de Murcia, 30071 Murcia, Spain
Gabriel García
Departamento de Química Inorgánica, Facultad de Química, Campus Regional de Excelencia “Campus Mare Nostrum”, Universidad de Murcia, 30071 Murcia, Spain
When the [Ru(p-cymene)(μ-Cl)Cl]2 complex is made to react, in dichloromethane, with the following ligands: 2-aminobenzonitrile (2abn), 4-aminobenzonitrile (4abn), 2-aminopyridine (2ampy) and 4-aminopyridine (4ampy), after addition of hexane, the following compounds are obtained: [Ru(p-cymene)Cl2(2abn)] (I), [Ru(p-cymene)Cl2(4abn)] (II), [Ru(p-cymene)Cl2(2ampy] (III) and [Ru(p-cymene)Cl2(μ-(4ampy)] (IV). All the compounds are characterized by elemental analysis of carbon, hydrogen and nitrogen, proton nuclear magnetic resonance, COSY 1H-1H, high-resolution mass spectrometry (ESI), thermogravimetry and single-crystal X-ray diffraction (the crystal structure of III is reported and compared with the closely related literature of II). The cytotoxicity effects of complexes were described for cervical cancer HeLa cells via 3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyltetrazolium bromide (MTT) assay. The results demonstrate a low in vitro anticancer potential of the complexes.
